These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Eprosartan effect on fibrinolytic/hemostatic variables in arterial hypertension: a comparative study to losartan. Makris TK; Stavroulakis G; Papadopoulos DP; Krespi P; Hatzizacharias A; Zilidis A; Tsoukala C; Votteas VE Drugs Exp Clin Res; 2004; 30(3):125-32. PubMed ID: 15366789 [TBL] [Abstract][Full Text] [Related]
3. AT1 blockers and uric acid metabolism: are there relevant differences? Puig JG; Torres R; Ruilope LM J Hypertens Suppl; 2002 Jun; 20(5):S29-31. PubMed ID: 12184060 [TBL] [Abstract][Full Text] [Related]
4. Effects of neutral endopeptidase inhibition and combined angiotensin converting enzyme and neutral endopeptidase inhibition on angiotensin and bradykinin peptides in rats. Campbell DJ; Anastasopoulos F; Duncan AM; James GM; Kladis A; Briscoe TA J Pharmacol Exp Ther; 1998 Nov; 287(2):567-77. PubMed ID: 9808682 [TBL] [Abstract][Full Text] [Related]
5. Adrenal angiotensin: origin and site of generation. van Kats JP; Chai W; Duncker DJ; Schalekamp MA; Danser AH Am J Hypertens; 2005 Aug; 18(8):1104-10. PubMed ID: 16109325 [TBL] [Abstract][Full Text] [Related]
6. Effects of losartan on angiotensin and bradykinin peptides and angiotensin-converting enzyme. Campbell DJ; Kladis A; Valentijn AJ J Cardiovasc Pharmacol; 1995 Aug; 26(2):233-40. PubMed ID: 7475048 [TBL] [Abstract][Full Text] [Related]
7. AT1 antagonism by eprosartan lowers heart rate variability and baroreflex gain. Heusser K; Vitkovsky J; Schmieder RE; Schobel HP Auton Neurosci; 2003 Aug; 107(1):45-51. PubMed ID: 12927226 [TBL] [Abstract][Full Text] [Related]
8. Disparate systemic and renal blocking properties of angiotensin II antagonists during exogenous angiotensin II administration: implications for treatment. Willemsen JM; Rabelink TJ; Boer P; Gaillard CA J Hum Hypertens; 2004 Dec; 18(12):857-63. PubMed ID: 15361886 [TBL] [Abstract][Full Text] [Related]
9. Different effects of transdermal and oral hormone replacement therapy on the renin-angiotensin system, plasma bradykinin level, and blood pressure of normotensive postmenopausal women. Ichikawa J; Sumino H; Ichikawa S; Ozaki M Am J Hypertens; 2006 Jul; 19(7):744-9. PubMed ID: 16814131 [TBL] [Abstract][Full Text] [Related]
10. Losartan reduces monocyte chemoattractant protein-1 expression in aortic tissues of 2K1C hypertensive rats. Xie QY; Sun M; Yang TL; Sun ZL Int J Cardiol; 2006 Jun; 110(1):60-6. PubMed ID: 16242797 [TBL] [Abstract][Full Text] [Related]
11. Bradykinin contributes to the systemic hemodynamic effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure. Cruden NL; Witherow FN; Webb DJ; Fox KA; Newby DE Arterioscler Thromb Vasc Biol; 2004 Jun; 24(6):1043-8. PubMed ID: 15105283 [TBL] [Abstract][Full Text] [Related]
12. Atenolol and eprosartan: differential effects on central blood pressure and aortic pulse wave velocity. Dhakam Z; McEniery CM; Yasmin ; Cockcroft JR; Brown MJ; Wilkinson IB Am J Hypertens; 2006 Feb; 19(2):214-9. PubMed ID: 16448896 [TBL] [Abstract][Full Text] [Related]
13. Angiotensin-converting enzyme inhibition modifies angiotensin but not kinin peptide levels in human atrial tissue. Campbell DJ; Duncan AM; Kladis A Hypertension; 1999 Aug; 34(2):171-5. PubMed ID: 10454436 [TBL] [Abstract][Full Text] [Related]
14. Angiotensin II type 2 receptors contribute to vascular responses in spontaneously hypertensive rats treated with angiotensin II type 1 receptor antagonists. Cosentino F; Savoia C; De Paolis P; Francia P; Russo A; Maffei A; Venturelli V; Schiavoni M; Lembo G; Volpe M Am J Hypertens; 2005 Apr; 18(4 Pt 1):493-9. PubMed ID: 15831358 [TBL] [Abstract][Full Text] [Related]
15. An update on non-peptide angiotensin receptor antagonists and related RAAS modulators. Aulakh GK; Sodhi RK; Singh M Life Sci; 2007 Aug; 81(8):615-39. PubMed ID: 17692338 [TBL] [Abstract][Full Text] [Related]
16. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Koh KK; Quon MJ; Han SH; Chung WJ; Ahn JY; Seo YH; Kang MH; Ahn TH; Choi IS; Shin EK Circulation; 2004 Dec; 110(24):3687-92. PubMed ID: 15569835 [TBL] [Abstract][Full Text] [Related]
17. Angiotensin II formation by an alternative pathway during exercise in humans. Miura S; Ideishi M; Sakai T; Motoyama M; Kinoshita A; Sasaguri M; Tanaka H; Shindo M; Arakawa K J Hypertens; 1994 Oct; 12(10):1177-81. PubMed ID: 7836734 [TBL] [Abstract][Full Text] [Related]
18. Introduction: The pharmacological profile of eprosartan--implications for cerebrovascular and cardiovascular risk reduction. de la Sierra A; Ram CV Curr Med Res Opin; 2007 Nov; 23 Suppl 5():S1-3. PubMed ID: 18093407 [TBL] [Abstract][Full Text] [Related]
19. Genetic clamping of renin gene expression induces hypertension and elevation of intrarenal Ang II levels of graded severity in Cyp1a1-Ren2 transgenic rats. Mitchell KD; Bagatell SJ; Miller CS; Mouton CR; Seth DM; Mullins JJ J Renin Angiotensin Aldosterone Syst; 2006 Jun; 7(2):74-86. PubMed ID: 17083061 [TBL] [Abstract][Full Text] [Related]
20. Effect of eprosartan on the sympathetic response to cold pressor test in healthy volunteers. Israel A; Zavala LE; Cierco M; Gutierrez A; del Rosario Garrido M Auton Neurosci; 2006 Jun; 126-127():179-84. PubMed ID: 16630748 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]